Skip to main content
Top
Published in: Endocrine 3/2020

01-06-2020 | Pituitary Adenoma | Original Article

GPR64 promotes cAMP pathway in tumor aggressiveness in sparsely granulated growth hormone cell adenomas

Authors: Tao Xie, Yifan Tang, Rongkui Luo, Xiaobiao Zhang, Silin Wu, Ye Gu, Tengfei Liu, Fan Hu

Published in: Endocrine | Issue 3/2020

Login to get access

Abstract

Purpose

There is an increasing agreement that acromegaly caused by growth hormone (GH) cell adenoma has two distinct subtypes: densely granulated (DG) and sparsely granulated (SG). We hypothesized that differential molecular signatures may explain their behavior.

Methods

Total transcriptome sequencing was performed on ten DG and seven SG adenomas. The differentially expressed RNAs were identified by bioinformatic analyses, and a candidate RNA was verified by quantitative real-time PCR. Immunohistochemical staining was also performed to detect the protein expression of the candidate. Clinical parameters were correlated with protein expression. Subsequently, cell proliferation, colony formation, and cell cycle progression were analyzed after knockdown of the candidate in pituitary GH3 cells. Activation of the cAMP pathway was assessed by ELISA and Western blot.

Results

We confirmed that there were obvious differentially expressed genes between the subtypes. Through gene profiling, we discovered that an orphan adhesion G protein-coupled receptor, GPR64, was overexpressed in more aggressive SG adenomas. Noticeably, GPR64 knockdown significantly inhibited the proliferation of GH3 tumor cells and decreased colony formation. The knockdown also induced cell cycle arrest in GH3 tumor cells. Further studies revealed that GPR64 knockdown decreased cAMP levels and the ratios of p-CREB/CREB, indicating that it suppressed the cAMP/CREB pathway.

Conclusions

Our results indicated that GPR64 may promote aggressiveness in SG-type GH cell adenomas and that it is a key factor regulating the cAMP pathway to promote aggressiveness of GH cell adenomas.
Appendix
Available only for authorised users
Literature
1.
go back to reference A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102–152 (2004)PubMed A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102–152 (2004)PubMed
2.
go back to reference A. Ben-Shlomo, S. Melmed, Acromegaly. Endocrinol. Metab. Clin. N. Am. 37(1), 101–122 (2008) A. Ben-Shlomo, S. Melmed, Acromegaly. Endocrinol. Metab. Clin. N. Am. 37(1), 101–122 (2008)
3.
go back to reference S. Melmed, Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7(5), 257–266 (2011)PubMed S. Melmed, Pathogenesis of pituitary tumors. Nat. Rev. Endocrinol. 7(5), 257–266 (2011)PubMed
5.
go back to reference E. Horvath, K. Kovacs, Pathology of acromegaly. Neuroendocrinology 83(3-4), 161–165 (2006)PubMed E. Horvath, K. Kovacs, Pathology of acromegaly. Neuroendocrinology 83(3-4), 161–165 (2006)PubMed
6.
go back to reference S.L. Asa, W. Kucharczyk, S. Ezzat, Pituitary acromegaly: not one disease. Endocr. Relat. Cancer 24(3), 1–4 (2017) S.L. Asa, W. Kucharczyk, S. Ezzat, Pituitary acromegaly: not one disease. Endocr. Relat. Cancer 24(3), 1–4 (2017)
7.
go back to reference K. Kiseljak-Vassiliades, N.E. Carlson, M.T. Borges, B.K. Kleinschmidt-DeMasters, K.O. Lillehei, J.M. Kerr, M.E. Wierman, Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1), 231–241 (2015)PubMed K. Kiseljak-Vassiliades, N.E. Carlson, M.T. Borges, B.K. Kleinschmidt-DeMasters, K.O. Lillehei, J.M. Kerr, M.E. Wierman, Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1), 231–241 (2015)PubMed
8.
go back to reference B. Mayr, R. Buslei, M. Theodoropoulou, G.K. Stalla, M. Buchfelder, C. Schofl, Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur. J. Endocrinol. 169(4), 391–400 (2013)PubMed B. Mayr, R. Buslei, M. Theodoropoulou, G.K. Stalla, M. Buchfelder, C. Schofl, Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur. J. Endocrinol. 169(4), 391–400 (2013)PubMed
9.
go back to reference S.L. Asa, S. Ezzat, The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4, 97–126 (2009)PubMed S.L. Asa, S. Ezzat, The pathogenesis of pituitary tumors. Annu. Rev. Pathol. 4, 97–126 (2009)PubMed
10.
go back to reference I. Potorac, P. Petrossians, A.F. Daly, O. Alexopoulou, S. Borot, M. Sahnoun-Fathallah, F. Castinetti, F. Devuyst, M.L. Jaffrain-Rea, C. Briet, F. Luca, M. Lapoirie, F. Zoicas, I. Simoneau, A.M. Diallo, A. Muhammad, F. Kelestimur, E. Nazzari, R.G. Centeno, S.M. Webb, M.L. Nunes, V. Hana, V. Pascal-Vigneron, I. Ilovayskaya, F. Nasybullina, S. Achir, D. Ferone, S.J. Neggers, B. Delemer, J.M. Petit, C. Schofl, G. Raverot, B. Goichot, P. Rodien, B. Corvilain, T. Brue, F. Schillo, L. Tshibanda, D. Maiter, J.F. Bonneville, A. Beckers, T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr. Relat. Cancer 23(11), 871–881 (2016)PubMed I. Potorac, P. Petrossians, A.F. Daly, O. Alexopoulou, S. Borot, M. Sahnoun-Fathallah, F. Castinetti, F. Devuyst, M.L. Jaffrain-Rea, C. Briet, F. Luca, M. Lapoirie, F. Zoicas, I. Simoneau, A.M. Diallo, A. Muhammad, F. Kelestimur, E. Nazzari, R.G. Centeno, S.M. Webb, M.L. Nunes, V. Hana, V. Pascal-Vigneron, I. Ilovayskaya, F. Nasybullina, S. Achir, D. Ferone, S.J. Neggers, B. Delemer, J.M. Petit, C. Schofl, G. Raverot, B. Goichot, P. Rodien, B. Corvilain, T. Brue, F. Schillo, L. Tshibanda, D. Maiter, J.F. Bonneville, A. Beckers, T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr. Relat. Cancer 23(11), 871–881 (2016)PubMed
11.
go back to reference O. Mete, M.B. Lopes, Overview of the 2017 WHO classification of pituitary tumors. Endocr. Pathol. 28(3), 228–243 (2017)PubMed O. Mete, M.B. Lopes, Overview of the 2017 WHO classification of pituitary tumors. Endocr. Pathol. 28(3), 228–243 (2017)PubMed
12.
go back to reference A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82–91 (2008)PubMed A. Obari, T. Sano, K. Ohyama, E. Kudo, Z.R. Qian, A. Yoneda, N. Rayhan, M. Mustafizur Rahman, S. Yamada, Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr. Pathol. 19(2), 82–91 (2008)PubMed
13.
go back to reference Y. Bakhtiar, H. Hirano, K. Arita, S. Yunoue, S. Fujio, A. Tominaga, T. Sakoguchi, K. Sugiyama, K. Kurisu, J. Yasufuku-Takano, K. Takano, Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163(4), 531–539 (2010)PubMed Y. Bakhtiar, H. Hirano, K. Arita, S. Yunoue, S. Fujio, A. Tominaga, T. Sakoguchi, K. Sugiyama, K. Kurisu, J. Yasufuku-Takano, K. Takano, Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur. J. Endocrinol. 163(4), 531–539 (2010)PubMed
14.
go back to reference S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96–102 (2012) S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96–102 (2012)
15.
go back to reference D. Araç, A.A. Boucard, M.F. Bolliger, J. Nguyen, S.M. Soltis, T.C. Südhof, A.T. Brunger, A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. Embo. J. 31(6), 1364–1378 (2012)PubMedPubMedCentral D. Araç, A.A. Boucard, M.F. Bolliger, J. Nguyen, S.M. Soltis, T.C. Südhof, A.T. Brunger, A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. Embo. J. 31(6), 1364–1378 (2012)PubMedPubMedCentral
16.
go back to reference B. Davies, C. Kirchhoff, Adhesion-GPCRs in the male reproductive tract. Adv. Exp. Med. Biol. 706, 179–188 (2010)PubMed B. Davies, C. Kirchhoff, Adhesion-GPCRs in the male reproductive tract. Adv. Exp. Med. Biol. 706, 179–188 (2010)PubMed
17.
go back to reference N. Balenga, P. Azimzadeh, J.A. Hogue, P.N. Staats, Y. Shi, J. Koh, H. Dressman, J.A. Olson Jr., Orphan adhesion GPCR GPR64/ADGRG2 is overexpressed in parathyroid tumors and attenuates calcium-sensing receptor-mediated signaling. J. Bone Miner. Res. 32(3), 654–666 (2017)PubMed N. Balenga, P. Azimzadeh, J.A. Hogue, P.N. Staats, Y. Shi, J. Koh, H. Dressman, J.A. Olson Jr., Orphan adhesion GPCR GPR64/ADGRG2 is overexpressed in parathyroid tumors and attenuates calcium-sensing receptor-mediated signaling. J. Bone Miner. Res. 32(3), 654–666 (2017)PubMed
18.
go back to reference M.C. Peeters, M. Fokkelman, B. Boogaard, K.L. Egerod, B. van de Water, I.J.A.P.,T.W. Schwartz, The adhesion G protein-coupled receptor G2 (ADGRG2/GPR64) constitutively activates SRE and NFkappaB and is involved in cell adhesion and migration. Cell. Signal. 27(12), 2579–2588 (2015)PubMed M.C. Peeters, M. Fokkelman, B. Boogaard, K.L. Egerod, B. van de Water, I.J.A.P.,T.W. Schwartz, The adhesion G protein-coupled receptor G2 (ADGRG2/GPR64) constitutively activates SRE and NFkappaB and is involved in cell adhesion and migration. Cell. Signal. 27(12), 2579–2588 (2015)PubMed
19.
go back to reference J.Y. Yoo, J.I. Ahn, T.H. Kim, S. Yu, J.Y. Ahn, J.M. Lim, J.-W. Jeong, G-protein coupled receptor 64 is required for decidualization of endometrial stromal cells. Sci. Rep. 7(1), 5021–5021 (2017)PubMedPubMedCentral J.Y. Yoo, J.I. Ahn, T.H. Kim, S. Yu, J.Y. Ahn, J.M. Lim, J.-W. Jeong, G-protein coupled receptor 64 is required for decidualization of endometrial stromal cells. Sci. Rep. 7(1), 5021–5021 (2017)PubMedPubMedCentral
20.
go back to reference G.H. Richter, A. Fasan, K. Hauer, T.G. Grunewald, C. Berns, S. Rossler, I. Naumann, M.S. Staege, S. Fulda, I. Esposito, S. Burdach, G-protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1. J. Pathol. 230(1), 70–81 (2013)PubMed G.H. Richter, A. Fasan, K. Hauer, T.G. Grunewald, C. Berns, S. Rossler, I. Naumann, M.S. Staege, S. Fulda, I. Esposito, S. Burdach, G-protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1. J. Pathol. 230(1), 70–81 (2013)PubMed
21.
go back to reference D.G. Altman, Practical Statistics for Medical Research (Chapman and Hall, London, 1991) D.G. Altman, Practical Statistics for Medical Research (Chapman and Hall, London, 1991)
22.
go back to reference L.B. Butz, S.E. Sullivan, W.F. Chandler, A.L. Barkan, “Micromegaly”: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary 19(6), 547–551 (2016)PubMed L.B. Butz, S.E. Sullivan, W.F. Chandler, A.L. Barkan, “Micromegaly”: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary 19(6), 547–551 (2016)PubMed
23.
go back to reference M.R. Gadelha, L. Kasuki, M. Korbonits, Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol. Metab. 24(5), 238–246 (2013)PubMed M.R. Gadelha, L. Kasuki, M. Korbonits, Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol. Metab. 24(5), 238–246 (2013)PubMed
24.
go back to reference S.L. Asa, R. Digiovanni, J. Jiang, M.L. Ward, K. Loesch, S. Yamada, T. Sano, K. Yoshimoto, S.J. Frank, S. Ezzat, A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 67(15), 7505–7511 (2007)PubMed S.L. Asa, R. Digiovanni, J. Jiang, M.L. Ward, K. Loesch, S. Yamada, T. Sano, K. Yoshimoto, S.J. Frank, S. Ezzat, A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 67(15), 7505–7511 (2007)PubMed
25.
go back to reference A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32(2), 247–271 (2011)PubMed A. Colao, R.S. Auriemma, G. Lombardi, R. Pivonello, Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32(2), 247–271 (2011)PubMed
26.
go back to reference S. Larkin, R. Reddy, N. Karavitaki, S. Cudlip, J. Wass, O. Ansorge, Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur. J. Endocrinol. 168(4), 491–499 (2013)PubMed S. Larkin, R. Reddy, N. Karavitaki, S. Cudlip, J. Wass, O. Ansorge, Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur. J. Endocrinol. 168(4), 491–499 (2013)PubMed
27.
go back to reference M. Kato, N. Inoshita, T. Sugiyama, Y. Tani, M. Shichiri, T. Sano, S. Yamada, Y. Hirata, Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr. J. 59(3), 221–228 (2012)PubMed M. Kato, N. Inoshita, T. Sugiyama, Y. Tani, M. Shichiri, T. Sano, S. Yamada, Y. Hirata, Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr. J. 59(3), 221–228 (2012)PubMed
28.
go back to reference C. Capatina, J.A. Wass, 60 years of neuroendocrinology: acromegaly. J. Endocrinol. 226(2), 141–160 (2015) C. Capatina, J.A. Wass, 60 years of neuroendocrinology: acromegaly. J. Endocrinol. 226(2), 141–160 (2015)
29.
go back to reference W.J. Ansorge, Next-generation DNA sequencing techniques. N. Biotechnol. 25(4), 195–203 (2009)PubMed W.J. Ansorge, Next-generation DNA sequencing techniques. N. Biotechnol. 25(4), 195–203 (2009)PubMed
30.
go back to reference A.S. Hauser, M.M. Attwood, M. Rask-Andersen, H.B. Schioth, D.E. Gloriam, Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16(12), 829–842 (2017)PubMedPubMedCentral A.S. Hauser, M.M. Attwood, M. Rask-Andersen, H.B. Schioth, D.E. Gloriam, Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16(12), 829–842 (2017)PubMedPubMedCentral
31.
go back to reference K.L. Whittier, E.A. Boese, K.N. Gibson-Corley, P.A. Kirby, B.W. Darbro, Q. Qian, W.J. Ingram, T. Robertson, M. Remke, M.D. Taylor, M.S. O’Dorisio, G-protein coupled receptor expression patterns delineate medulloblastoma subgroups. Acta Neuropathol. Commun. 1, 66–66 (2013)PubMedPubMedCentral K.L. Whittier, E.A. Boese, K.N. Gibson-Corley, P.A. Kirby, B.W. Darbro, Q. Qian, W.J. Ingram, T. Robertson, M. Remke, M.D. Taylor, M.S. O’Dorisio, G-protein coupled receptor expression patterns delineate medulloblastoma subgroups. Acta Neuropathol. Commun. 1, 66–66 (2013)PubMedPubMedCentral
32.
go back to reference T. Cuny, C. Gerard, A. Saveanu, A. Barlier, A. Enjalbert, Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy. Ann. N. Y. Acad. Sci. 1220, 60–70 (2011)PubMed T. Cuny, C. Gerard, A. Saveanu, A. Barlier, A. Enjalbert, Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy. Ann. N. Y. Acad. Sci. 1220, 60–70 (2011)PubMed
33.
go back to reference C.Di Pasquale, E. Gentilin, S. Falletta, M. Bellio, M. Buratto, E. Degli, M. Uberti, Chiara Zatelli, PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line. Endocrine 60(2), 308–316 (2018)PubMed C.Di Pasquale, E. Gentilin, S. Falletta, M. Bellio, M. Buratto, E. Degli, M. Uberti, Chiara Zatelli, PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line. Endocrine 60(2), 308–316 (2018)PubMed
34.
go back to reference A.K. Roof, A. Gutierrez-Hartmann, Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific. Mol. Cell. Endocrinol. 5(463), 87–96 (2018) A.K. Roof, A. Gutierrez-Hartmann, Consider the context: Ras/ERK and PI3K/AKT/mTOR signaling outcomes are pituitary cell type-specific. Mol. Cell. Endocrinol. 5(463), 87–96 (2018)
35.
go back to reference T. Xie, T. Liu, X. Zhang, L. Chen, R. Luo, W. Sun, F. Hu, Y. Yu, Y. Gu, Z. Lu, Time to revive the value of the pseudocapsule in endoscopic endonasal transsphenoidal surgery for growth hormone adenomas. World Neurosurg. 89, 65–71 (2016)PubMed T. Xie, T. Liu, X. Zhang, L. Chen, R. Luo, W. Sun, F. Hu, Y. Yu, Y. Gu, Z. Lu, Time to revive the value of the pseudocapsule in endoscopic endonasal transsphenoidal surgery for growth hormone adenomas. World Neurosurg. 89, 65–71 (2016)PubMed
36.
go back to reference S. Petersenn, Management of aggressive pituitary tumors—a 2019 update. Horm. Metab. Res. 51(12), 755–764 (2019)PubMed S. Petersenn, Management of aggressive pituitary tumors—a 2019 update. Horm. Metab. Res. 51(12), 755–764 (2019)PubMed
Metadata
Title
GPR64 promotes cAMP pathway in tumor aggressiveness in sparsely granulated growth hormone cell adenomas
Authors
Tao Xie
Yifan Tang
Rongkui Luo
Xiaobiao Zhang
Silin Wu
Ye Gu
Tengfei Liu
Fan Hu
Publication date
01-06-2020
Publisher
Springer US
Published in
Endocrine / Issue 3/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02263-y

Other articles of this Issue 3/2020

Endocrine 3/2020 Go to the issue